134 related articles for article (PubMed ID: 12975594)
1. Role of oral blockade of platelet glycoprotein IIb/IIIa on neutrophil activation in patients with acute coronary syndromes.
Serrano CV; Nicolau JC; Venturinelli M; Baracioli LM; Anders RJ; Cannon CP; Ramires JA
Cardiovasc Drugs Ther; 2003 Mar; 17(2):129-32. PubMed ID: 12975594
[TBL] [Abstract][Full Text] [Related]
2. Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes.
O'Connor FF; Shields DC; Fitzgerald A; Cannon CP; Braunwald E; Fitzgerald DJ
Blood; 2001 Dec; 98(12):3256-60. PubMed ID: 11719362
[TBL] [Abstract][Full Text] [Related]
3. Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes.
Cox D; Smith R; Quinn M; Theroux P; Crean P; Fitzgerald DJ
J Am Coll Cardiol; 2000 Nov; 36(5):1514-9. PubMed ID: 11079651
[TBL] [Abstract][Full Text] [Related]
4. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial.
Cannon CP; McCabe CH; Wilcox RG; Langer A; Caspi A; Berink P; Lopez-Sendon J; Toman J; Charlesworth A; Anders RJ; Alexander JC; Skene A; Braunwald E
Circulation; 2000 Jul; 102(2):149-56. PubMed ID: 10889124
[TBL] [Abstract][Full Text] [Related]
5. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa.
Schneider DJ; Taatjes DJ; Sobel BE
Cardiovasc Res; 2000 Jan; 45(2):437-46. PubMed ID: 10728364
[TBL] [Abstract][Full Text] [Related]
6. Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an OPUS-TIMI 16 substudy. Orbofiban in Patients with Unstable coronary syndromes. Thrombolysis In Myocardial Infarction.
Holmes MB; Sobel BE; Cannon CP; Schneider DJ
Am J Cardiol; 2000 Feb; 85(4):491-3, A10. PubMed ID: 10728957
[TBL] [Abstract][Full Text] [Related]
7. Drug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial.
Scirica BM; Cannon CP; Cooper R; Aster RH; Brassard J; McCabe CH; Charlesworth A; Skene AM; Braunwald E
J Thromb Thrombolysis; 2006 Oct; 22(2):95-102. PubMed ID: 17008974
[TBL] [Abstract][Full Text] [Related]
8. Learning from the recently completed oral glycoprotein IIb/IIIa receptor antagonist trials.
Cannon CP
Clin Cardiol; 2000 Nov; 23 Suppl 6(Suppl 6):VI-14-7. PubMed ID: 11129681
[TBL] [Abstract][Full Text] [Related]
9. Orbofiban: an orally active GPIIb/IIIa platelet receptor antagonist.
Nicholson NS; Abood NA; Panzer-Knodle SG; Frederick LG; Page JD; Salyers AK; Suleymanov OD; Szalony JA; Taite BB; Anders RJ
Med Res Rev; 2001 May; 21(3):211-26. PubMed ID: 11301411
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy between the glycoprotein IIb/IIIa antagonists roxifiban and orbofiban in inhibiting platelet responses in flow models of thrombosis.
Mousa SA; Abulencia JP; McCarty OJ; Turner NA; Konstantopoulos K
J Cardiovasc Pharmacol; 2002 Apr; 39(4):552-60. PubMed ID: 11904529
[TBL] [Abstract][Full Text] [Related]
11. Statins are associated with lower risk of gastrointestinal bleeding in patients with unstable coronary syndromes: analysis of the Orbofiban in Patients with Unstable coronary Syndromes-Thrombolysis In Myocardial Infarction 16 (OPUS-TIMI 16) trial.
Atar S; Cannon CP; Murphy SA; Rosanio S; Uretsky BF; Birnbaum Y
Am Heart J; 2006 May; 151(5):976.e1-6. PubMed ID: 16644315
[TBL] [Abstract][Full Text] [Related]
12. Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndromes: are we doing enough? Results from the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study.
Cotter G; Cannon CP; McCabe CH; Michowitz Y; Kaluski E; Charlesworth A; Milo O; Bentley J; Blatt A; Krakover R; Zimlichman R; Reisin L; Marmor A; Lewis B; Vered Z; Caspi A; Braunwald E;
Am Heart J; 2003 Apr; 145(4):622-7. PubMed ID: 12679757
[TBL] [Abstract][Full Text] [Related]
13. Differential effect of the GPIIb/IIIa antagonist orbofiban on human platelet aggregate formation in vitro.
Racanelli AL; Gibbs SK; Zondlo SC; Seiffert DA; Friedman SM; Feuerstein GZ
Thromb Res; 2003 May; 110(2-3):99-105. PubMed ID: 12893024
[TBL] [Abstract][Full Text] [Related]
14. The contribution of genetic factors to thrombotic and bleeding outcomes in coronary patients randomised to IIb/IIIa antagonists.
Shields DC; Fitzgerald AP; O'Neill PA; Muckian C; Kenny D; Moran B; Cannon CP; Byrne CE; Fitzgerald DJ
Pharmacogenomics J; 2002; 2(3):182-90. PubMed ID: 12082590
[TBL] [Abstract][Full Text] [Related]
15. Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopenia.
Peter K; Straub A; Kohler B; Volkmann M; Schwarz M; Kübler W; Bode C
Am J Cardiol; 1999 Sep; 84(5):519-24. PubMed ID: 10482148
[TBL] [Abstract][Full Text] [Related]
16. Antiplatelet and antithrombotic effects of orbofiban, a new orally active GPIIb/IIIa antagonist, in guinea pigs.
Ogawa T; Sugidachi A; Naganuma H; Asai F
Thromb Res; 2000 Mar; 97(5):307-15. PubMed ID: 10709906
[TBL] [Abstract][Full Text] [Related]
17. Effects of glycoprotein IIb/IIIa antagonists on platelet activation: development of a transfer method to mimic peak to trough receptor occupancy.
Billheimer JT; He B; Spitz SM; Stern AM; Seiffert D
Thromb Res; 2002 Sep; 107(6):303-17. PubMed ID: 12565717
[TBL] [Abstract][Full Text] [Related]
18. Glycoprotein IIb/IIIa antagonists induce apoptosis in rat cardiomyocytes by caspase-3 activation.
Adderley SR; Fitzgerald DJ
J Biol Chem; 2000 Feb; 275(8):5760-6. PubMed ID: 10681563
[TBL] [Abstract][Full Text] [Related]
19. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
Bhatt DL; Topol EJ
JAMA; 2000 Sep; 284(12):1549-58. PubMed ID: 11000650
[TBL] [Abstract][Full Text] [Related]
20. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.
Dyke CM
Am Heart J; 1999 Oct; 138(4 Pt 2):307-16. PubMed ID: 10502236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
